SUCRA and P scores for ranking of maintenance agents based on PFS and OS for transplant-eligible patients
| Maintenance agent . | SUCRA . | P score . |
|---|---|---|
| All cytogenetic risk groups | ||
| Len | 88% | 90% |
| Dara | 75% | 77% |
| Ixa | 35% | 33% |
| Placebo | 2% | 0.05% |
| All cytogenetic risk groups: sensitivity analysis using data for CASSIOPEIA without Dara induction | ||
| Len | 69% | 67% |
| Dara | 96% | 99% |
| Ixa | 33% | 33% |
| Placebo | 2% | 0.05% |
| Cytogenetic high risk | ||
| Len | 67% | 67% |
| Dara | 75% | 76% |
| Ixa | 47% | 47% |
| Placebo | 12% | 9% |
| Cytogenetic standard risk | ||
| Len | 90% | 100% |
| Dara | 55% | 58% |
| Ixa | 46% | 42% |
| Placebo | 9% | 0.05% |
| Maintenance agent . | SUCRA . | P score . |
|---|---|---|
| All cytogenetic risk groups | ||
| Len | 88% | 90% |
| Dara | 75% | 77% |
| Ixa | 35% | 33% |
| Placebo | 2% | 0.05% |
| All cytogenetic risk groups: sensitivity analysis using data for CASSIOPEIA without Dara induction | ||
| Len | 69% | 67% |
| Dara | 96% | 99% |
| Ixa | 33% | 33% |
| Placebo | 2% | 0.05% |
| Cytogenetic high risk | ||
| Len | 67% | 67% |
| Dara | 75% | 76% |
| Ixa | 47% | 47% |
| Placebo | 12% | 9% |
| Cytogenetic standard risk | ||
| Len | 90% | 100% |
| Dara | 55% | 58% |
| Ixa | 46% | 42% |
| Placebo | 9% | 0.05% |
Dara, daratumumab; Ixa, ixazomib; Len, lenalidomide.